



Ogier Guernsey advises Stanley Capital on new investment structure and acquisition of Noden Pharma

Deals - 01/10/2020

Ogier's Guernsey team has assisted Stanley Capital with the establishment of a Guernsey investment structure and the acquisition of Noden Pharma DAC and Noden Pharma USA (**Noden**), a leading speciality pharmaceutical company.

The multi-disciplinary Ogier team worked with Stanley Capital, lead counsel Willkie Farr & Gallagher (London) LLP and alterDomus. The team was led by partner Bryon Rees and senior associate Michelle Watson Bunn, with support from partners Tim Clipstone and Bryan De Verneuil-Smith, senior associate Charlotte Brown and associate Henry Simpson.

Bryon Rees commented: "We are delighted to have supported Stanley Capital and its advisors on this new investment structure and the initial acquisition, creating a solid base for future growth into a leading pharma platform."

Noden is focused on providing unique, complex to manufacture prescription medicines for cardiovascular patients who are intolerant to mainstream treatments. It is the first acquisition and a core platform for implementing a strategy to consolidate the mature product speciality pharma marketplace. Stanley Capital, working alongside Noden's management team, will pursue a value investment philosophy, targeting the acquisition of multiple drug portfolios to create a differentiated and highly cash generative portfolio of attractive medicines with established operational, technical, or patent-led barriers to entry.

Simon Cottle, partner at Stanley Capital, said: "The acquisition of Noden is the culmination of years of thematic research into the specialty pharmaceuticals sector, which identified the company as a strong buy and build platform. We look forward to working with Noden's excellent management team and our industry advisors to build the company into a leading pharma platform, providing essential treatments for patients with unique and difficult to treat conditions."

Stanley Capital is a private equity partnership pursuing repeatable relative value and thematic investment strategies in technology, healthcare, and sustainability, targeting businesses with enterprise values of \$250mn to \$2.5bn.

About Ogier

Ogier is a professional services firm with the knowledge and expertise to handle the most demanding and complex transactions and provide expert, efficient and cost-effective services to all our clients. We regularly win awards for the quality of our client service, our work and our people.

Disclaimer

This client briefing has been prepared for clients and professional associates of Ogier. The information and expressions of opinion which it contains are not intended to be a comprehensive study or to provide legal advice and should not be treated as a substitute for specific advice concerning individual situations.

Regulatory information can be found under [Legal Notice](#)

Meet the Author



Bryon Rees

Partner

Guernsey

E: bryon.rees@ogier.com

T: [+44 1481 752312](tel:+441481752312)

Key Contacts



Tim Clipstone

Partner

British Virgin Islands

Guernsey

E: tim.clipstone@ogier.com

T: [+44 1481 752265](tel:+441481752265)



Bryan De Verneuil-Smith

Partner

Guernsey

E: bryan.deverneuil-smith@ogier.com

T: [+44 1481 752357](tel:+441481752357)



Michelle Watson Bunn

Managing Associate

Guernsey

E: michelle.watsonbunn@ogier.com

T: [+44 1481 752220](tel:+441481752220)

Related Services

[Banking and Finance](#)

[Corporate](#)

[Investment Funds](#)

[Mergers and Acquisitions](#)

[Legal](#)

[Consulting](#)

Related Sectors

[Funds Hub](#)